Abstracts Archive - Page 2158 of 2425 - ACR Meeting Abstracts

Abstract Number: 1382 • 2013 ACR/ARHP Annual Meeting
The 11q23.3 Genomic Region – rs964184- Is Associated With Cardiovascular Disease In Patients With Rheumatoid Arthritis
Raquel lopez Mejias¹, Fernanda Genre², Mercedes García-Bermúdez³, Santos Castañeda⁴, Carlos González-Juanatey⁵, J. Llorca⁶, Encarnación Amigo⁷, Alfonso Corrales⁸, Jose A. Miranda-Filloy⁹, Javier Rueda-Gotor¹, Carmen Gomez vaquero¹⁰, Luis Rodriguez Rodriguez¹¹, Benjamin Fernandez Gutierrez¹¹, Alejandro Balsa¹², Dora Pascual-Salcedo¹³, Francisco Javier López-Longo¹⁴, Patricia Carreira¹⁵, Ricardo Blanco¹, Isidoro González-Alvaro¹⁶, Javier Martin¹⁷ and Miguel A. Gonzalez-Gay¹⁸, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain., Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ³Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁵Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, ⁶Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁷Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁸Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁹Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ¹⁰Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹²Rheumatology unit, La Paz University Hospital, Rheumatology, Madrid, Spain, ¹³La Paz University Hospital, Rheumatology, Madrid, Spain, ¹⁴Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ¹⁵Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁷Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, ¹⁸Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated atherosclerosis and high risk of cardiovascular (CV) disease. A recent meta-analysis has…
Abstract Number: 1383 • 2013 ACR/ARHP Annual Meeting
Validation Of Popliteal Lymph Node Phenotype and Bin Expansion As Biomarkers Of Rheumatoid Arthritis Knee Flare
Homaira Rahimi¹, Ronald Wood², Igor Kuzin³, Wakenda Tyler⁴, Gregory Dieudonne⁵, Stephen Kates⁶, Christopher T. Ritchlin³ and Edward M. Schwarz⁷, ¹Pediatrics, University of Rochester, Rochester, NY, ²Department of Urology, University of Rochester Medical Center, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Orthopedics, University of Rochester, Rochester, NY, ⁵Radiology, University of Rochester, Rochester, NY, ⁶Orthopedic Surgery, University of Rochester Medical Center, Rochester, NY, ⁷Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Factors precipitating joint flare in rheumatoid arthritis (RA) patients are poorly understood. Contrast enhanced (CE) MRI studies in murine models have identified popliteal lymph…
Abstract Number: 1384 • 2013 ACR/ARHP Annual Meeting
Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)
Yoshiya Tanaka¹, Tsutomu Takeuchi², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désiréé van der Heijde⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Keio University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RANKL is an essential factor for osteoclast differentiation and activation. Denosumab, a fully human monoclonal IgG2 antibody, is a potent inhibitor of RANKL and…
Abstract Number: 1385 • 2013 ACR/ARHP Annual Meeting
A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe¹, Yasuko Yamamoto³ and Kuniaki Saito³, ¹Orthopaedic Surgery, Gifu University, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Human Health Science, Kyoto University, Kyoto, Japan
Background/Purpose: Inflammatory cytokines and cell-mediated immunity function of mainly lymphocytes are complicatedly involved in disease onset of rheumatoid arthritis (RA). Recently, together with biologicals such…
Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting
Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis
Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…
Abstract Number: 1387 • 2013 ACR/ARHP Annual Meeting
Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function
Michelle J. Ormseth¹, Aihua Bian², Annette M. Oeser², Andrew Cunningham², Ayumi Shintani², S. Bobo Tanner³ and C. Michael Stein⁴, ¹Rheumatology, Vanderbilt Medical Center, Nashville, TN, ²Vanderbilt Medical Center, Nashville, TN, ³Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, ⁴School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is associated with insulin resistance and increased cardiovascular (CV) risk. Impaired vascular function, including arterial stiffness and endothelial dysfunction, is associated…
Abstract Number: 1388 • 2013 ACR/ARHP Annual Meeting
Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity
Peter Olsson¹, Elke Theander², Ulf Bergström³, Stefan Jovinge⁴, Lennart Jacobsson³ and Carl Turesson², ¹Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
Background/Purpose: Rheumatoid factor (RF) and other circulating heterophilic antibodies have been shown to interfere with antibody-based immunoassays, in particular with multiplex protein detection platforms. Previous…
Abstract Number: 1389 • 2013 ACR/ARHP Annual Meeting
Serum 14-3-3η Precedes and Independently Predicts The Development Of RA
Dirkjan van Schaardenburg¹, Reetinder Dhaliwal¹, Walter P. Maksymowych² and Anthony Marotta³, ¹Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: We have previously reported on a risk prediction rule for the development of rheumatoid arthritis (RA) in 374 seropositive (RF and/or ACPA) arthralgia patients,…
Abstract Number: 1391 • 2013 ACR/ARHP Annual Meeting
Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis
Saliha Harrach¹, Christian Schmidt-Lauber², Bayram Edemir³, Eberhard Schlatter¹, Thomas Pap⁴, Giuliano Ciarimboli¹ and Jessica Bertrand², ¹Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Münster, Germany, ²Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Münster, Münster, Germany, ³Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Muenster, Germany, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Tyrosine kinase inhibitors (TKI) are effective in treating malignant disorders and were suggested to also have an impact on non-malignant diseases such as rheumatoid…
Abstract Number: 1392 • 2013 ACR/ARHP Annual Meeting
The Expression Of Proto-Oncogene Survivin Splicing Variant 2B In Synovial Tissues and Blood From Patients With Rheumatoid Arthritis
Sho Mokuda^1,2, Tatsuhiko Miyazaki³, Junya Masumoto³, Masamoto Kanno⁴ and Kiyoshi Takasugi⁵, ¹Department of Immunology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, ²Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan, ³Department of Pathology, Division of Analyticalpathology, Ehime University Graduate School of Medicine, Toon, Japan, ⁴Department of Immunology, Graduate School of Biomedical Sciences, Hiroshima University, Hirosima, Japan, ⁵Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan
Background/Purpose: It has been reported that serum survivin level was an independent risk factor for predicting joint destruction in early rheumatoid arthritis (RA). The proto-oncogene…
Abstract Number: 1393 • 2013 ACR/ARHP Annual Meeting
Survivin But Not Fms-Like Tyrosine Kinase Ligand Is Up-Regulated Before Onset Of Rheumatoid Arthritis
Mikael Brink¹, Maria Bokarewa², Malin Erlandsson³ and Solbritt Rantapää Dahlqvist⁴, ¹Rheumatology, Umeå University, Umea, Sweden, ²Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden
Background/Purpose: Presence of antibodies against citrullinated peptides (anti-CCP2) and increased levels of cytokines and chemokines precedes the development of rheumatoid arthritis (RA) by several years.…
Abstract Number: 1394 • 2013 ACR/ARHP Annual Meeting
Self Reported Dental Symptoms Do Not Predict Periodontal Status In Patients With Rheumatoid Arthritis
Gurpal Buttar¹, Anastasia Zelekis-Cholakis², Robert Schroth², Hani S. El-Gabalawy³, Christine A. Peschken⁴ and Carol A. Hitchon⁵, ¹Department of Periodontics, University of Manitoba, Winnipeg, MB, Canada, ²Dental Diagnostics and Surgical Sciences, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴RR 149G, University of Manitoba, Winnipeg, MB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Periodontal disease (PD) and inflammatory arthritis (IA) share features of inflammation and bone loss and are linked in epidemiologic studies. Severe PD may be…
Abstract Number: 1395 • 2013 ACR/ARHP Annual Meeting
CXCL13 Is Elevated In Early and In Established Seropositive Rheumatoid Arthritis and Correlates With Rheumatoid Factor Levels
Jonathan D. Jones¹, B. JoNell Hamilton², Greg Challener³, Artur Fernandes⁴, Pierre Cossette⁵, Patrick Liang⁴, Ariel Masetto⁶, HA Menard⁷, Nathalie Carrier⁸, Gilles Boire⁴ and William Rigby⁹, ¹Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ²Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ³Rheumatology, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Rheumatology, McGill University, Montréal, QC, Canada, ⁸Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: CXCL13 is a B cell chemokine whose expression has been reported to be elevated in serum and synovium from patients with rheumatoid arthritis (RA). …
Abstract Number: 1396 • 2013 ACR/ARHP Annual Meeting
Survivin–positivity Increases Risk For RA and Has a Strong Additive Effect On The Shared Epitope Alleles and Antibodies To Citrullinated Peptides In Patients Of The Malaysian Epidemiological Investigation Of Rheumatoid Arthritis (MyEIRA) Study Group
Chun Lai Too¹, Shahnaz Murad², Malin Erlandsson³, Heselynn Hussein⁴, Wahinuddin Sulaiman⁵, Jasbir Singh Dhaliwal¹ and Maria Bokarewa³, ¹Institute for Medical Research, Allergy and Immunology Research Center, Jalan Pahang, Kuala Lumpur, Malaysia, ²Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia, ⁵Department of Medicine, Tengku Bainun Hospital, Ipoh, Perak, Malaysia
Background/Purpose: The human leukocyte antigen (HLA)-DRB1 with alleles that contain common amino acid motif QKRAA termed shared epitope (SE) confer the major locus of genetic…
Abstract Number: 1374 • 2013 ACR/ARHP Annual Meeting
NR1D1 Is a New Suppressor of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Invasion
Teresina Laragione^1,2 and Percio Gulko^1,2, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic autoimmune disease. Arthritis severity and joint damage predict clinical outcome and the risk for disability in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].